Drug & Clinical Pipeline Explorer
The Drug and clinical pipeline explorer shows approved and investigational small-molecule drugs, the clinical trials that tested them, and how far each drug has got. It runs in your browser: no account, and your searches are never sent to a server.
Two things to know first. Biologics (antibodies, proteins, peptides, vaccines, cell and gene therapies) are not included. Trials come from ClinicalTrials.gov only, so development registered nowhere else is invisible.
Quick start
- Search a drug name, research code (MK-1234) or ChEMBL ID. An NCT number opens that trial in the Trials tab.
- Click a drug to open its panel: structure, mechanism, approvals, safety and full trial history.
- Filters narrows the set, for example by target, disease area or designation. The four data groups apply to all three tabs; Drug status applies to the Drugs tab and Trial status to the Trials tab.
- Switch tabs: Drugs (one row per drug), Trials (one row per trial), Charts (the filtered set as charts).
- Copy link to this view saves the exact view, filters and sort included. Reset clears everything.
Hover any ? or underlined label for an explanation.
↑ Back to contentsFilters
| Group | What you can filter on |
|---|---|
| Find a drug | Name or code, target gene (EGFR), drug class by USAN stem (-tinib, or a word such as kinase), condition studied (MeSH) |
| Biology & classification | Disease area, pathway, action type (inhibitor, agonist…), WHO ATC class, route (oral, parenteral, topical) |
| Company & regulatory | Sponsor, NME (new molecular entity), designations: first-in-class, orphan, Breakthrough, Fast Track, accelerated or conditional approval, PRIME, QIDP, withdrawn for safety, black-box warning |
| Evidence & chemistry | Investigational trial-linked only, hide drugs with no evidence, prodrug, natural product, diagnostic / contrast agent |
| Drug status | Approved or not (with an approval-date range), progress (see Approval and progress), last activity, ongoing trial at a given phase |
| Trial status | Active, completed (with an end-date range), stopped (by reason: safety, lack of efficacy, regulatory, administrative, unclear), unknown, expanded access |
Ticking several designations or chemistry boxes requires all of them. Ticking several statuses accepts any of them.
Pooled by compound (the default) merges each drug’s salt forms into one row, so sildenafil citrate counts as sildenafil. Per formulation shows every salt form separately. The switch affects Drugs and Charts, not Trials. Esters, prodrugs, metabolites and enantiomers are always separate drugs; the drug panel’s Related drugs card links them.
↑ Back to contentsDrugs
One row per drug. The tiles above the table count drugs, approved drugs, NMEs and drugs with no active development in your filtered set. That last tile also counts drugs with no trial data.
- Stage: the highest phase reached, or “Approved” with the regulator when known.
- Progress: whether development is moving (see Approval and progress).
- Trials: the trials that test this drug, with a bar split into completed, ongoing, stopped and stalled. Hover it for the other linked trials, where the drug is a comparator or background.
- Flags: NME, first-in-class, black-box warning and others.
Summary and Pipeline detail switch the column set; Pipeline detail shows a bar per phase. Click a column header to sort. Download CSV (first 50) exports the top 50 rows in the current sort.
The drug panel (click a row) has these cards: structure and identity, druglikeness, target and mechanism, related drugs, pharmacokinetics and metabolism, regulatory (FDA, EU-wide licences and their flags, generics), safety warnings and market withdrawals, controlled-substance schedule and liver-injury link, trial history, and formulations. Where trials stopped, Why they stopped lists each one by reason with its phase, year, disease and the sponsor’s own words. Show its trials in the Trials tab lists them all.
↑ Back to contentsTrials
One row per registered trial that tests a drug in your filtered set: trial ID, drugs, phase, status, start and end dates, disease and MeSH condition. Filter by trial ID or phase at the top of the tab.
Click a trial for its enrolment, who could take part, conditions studied, each drug’s role in it, and its outcome measures. The NCT number links to ClinicalTrials.gov. Hover a stopped trial’s status for the reason.
↑ Back to contentsCharts
Choose a chart under Visualization:
| Chart | What it shows |
|---|---|
| Pipeline landscape by… | Top 15 by Group by: disease area, condition, target, mechanism, pathway or sponsor, each bar split by stage. Rank by drugs in development now, or all drugs. With All drugs, a disease-area, mechanism or pathway bar opens its drugs. |
| Phase transition rates | The share of drugs that moved from each phase to the next, or to approval |
| First approvals per year | New approvals by year, with the latest listed underneath |
| Trial starts per year, by phase | How many trials of these drugs started each year |
| Why and when trials stop | Stop reasons by phase, and how often trials stop early |
| Development time (first trial → approval) | Years from first registered trial to first approval, for drugs approved in 2007 or later |
| Physicochemical trends of approved drugs | Molecular weight, cLogP, TPSA and six more descriptors by approval period |
Rates, approvals and trial starts cover the Last 20 yr by default; change it under Years. The approval, development-time and property charts leave out diagnostic agents unless you tick Diagnostic / contrast agent, which then shows only them.
Each chart states its question, headline numbers and how to read it. How this is counted gives the method. Small groups show counts (“8 of 10”) instead of percentages. Download chart (PNG) keeps the notes with the image; Download data (CSV) exports every row behind the chart, not only the bars drawn.
Charts use the drug filters but not the status filters; each chart says what it includes.
↑ Back to contentsApproval and progress
Every drug has two separate facts.
Approval comes from FDA, EMA and Japan’s PMDA records, plus approval years in ChEMBL and KEGG. ChEMBL approvals do not name a country. There is no Chinese (NMPA) source.
Progress compares the deepest phase with a trial still running against the deepest phase the drug has already finished:
| Progress | Meaning |
|---|---|
| Advancing | Running a trial deeper than anything it has finished or stopped |
| Active at peak | Running trials at its deepest phase so far |
| Fell back | Running trials only below its peak |
| No active development | No trial running at Phase 0–3 (running Phase 4 or unphased studies do not count) |
| No trial data | No linked trial tests this drug: a gap in our coverage, not an outcome |
Because the two are separate, a drug can be approved and have fallen back. “No active development” does not mean failed: a programme waiting for its readout looks the same as an abandoned one.
↑ Back to contentsTrial roles and stop reasons
Each drug in a trial gets a role, read from the trial’s arms:
- Investigational: the drug being tested.
- Comparator: the drug used as an active control.
- Background: given to every arm, such as standard therapy.
- Not assessable: the trial’s records do not say; listed, not counted.
Only investigational, interventional trials count toward a drug’s progress and trial total; observational and expanded-access studies do not. Hover a role for how it was decided.
Stop reasons are Open Targets’ classification of the sponsor’s text. Safety and lack of efficacy are verdicts on the drug; administrative reasons (enrolment, funding, business) are not. The sponsor’s own words are always shown, and where they disagree with the label, trust the words.
↑ Back to contentsData sources
| Source | What it adds |
|---|---|
| ChEMBL | The drug list, structures, properties, mechanisms, first approval years, warnings |
| ClinicalTrials.gov (AACT) | Trials: phase, status, dates, arms, eligibility, outcomes |
| Open Targets | Targets, indications, stop-reason classification |
| FDA | NME approvals, dates, applicants, designations |
| EMA | EU-wide licences, flags, orphan status, generics |
| PMDA | Japanese approvals |
| KEGG | More approvals (FDA, EMA, PMDA) and ATC classes |
| FDA GSRS | Missing ATC classes and mechanisms, controlled-substance schedules, LiverTox links; marked “from FDA GSRS” |
The data is rebuilt monthly; the date is under the Drugs table. Each build passes automated quality checks before it goes live.
↑ Back to contentsLimitations
- Small molecules only. Pembrolizumab, adalimumab and semaglutide are absent by design.
- “No trial data” mostly means old. Most approved drugs without trials were approved before trial registration began in 2007 (median first approval 1982). Phase 1 trials are also under-registered.
- Curation is partial. About 28% of drugs have a target and 21% an approved indication. A blank cell is a gap, not evidence of absence.
- Early transition rates read high. ClinicalTrials.gov under-records early failures, and a drug counts as moving on if any indication does. Compare cohorts within the tool; do not quote these as industry rates.
- 1982 means “1982 or earlier”. FDA dates every older approval as 1982.
- Do not compare therapeutic areas head to head. A drug that failed in five indications and advanced in one counts as advancing in all of them.
Research tool, not medical advice; approval status here is not a regulatory record. Questions, bugs or data issues: ambrosigen.com.
